Fig. 2

Anticancer activity of the combined treatment comprising the use of docetaxel (DTX) and 1,4-DMP in the model of human prostate cancer PC-3M-luc2 xenografted into prostate glands of BALB/c Nude mice. a Results of in vivo imaging of PC-3M-luc2 tumors performed on day 41 of the experiment. b Kinetics of the PC-3M-luc2 tumor growth in mice treated with docetaxel (DTX) and 1,4-DMP given either alone and in a comparison to the control group of animals. Days of drug administration are indicated with gray arrows for docetaxel (DTX) and dotted arrow for 1,4-DMP. c PC-3M-luc2 tumor weight measured on the last day of the experiment (day 46) (*p < 0.05 vs. control and 1,4-DMP). d Images of metastases localized in liver of the control animal, lymph node of docetaxel (DTX)-treated mouse and lungs of the 1,4-DMP-treated mouse (from left to right). e Images of bands obtained during Western blot analysis of protein expression in tumor tissue of (I) control animals and animals treated with (II) docetaxel (DTX), (III) 1,4-DMP and (IV) docetaxel (DTX) with 1,4-DMP. f E-cadherin : N-cadherin expression ratios in the samples of tumor tissue collected on the last day of the experiment. The total cellular content of E-cadherin (comprising protein characterized by the molecular weight of 130 and 100 kDa) and N-cadherin (comprising protein characterized by the molecular weight of 100 and 70 kDa) was first normalized to the content of β-actin and then used to determine E-cadherin to N-cadherin expression ratios. g The level of low molecular weight fragment of E-cadherin in PC-3M-luc2 tumors normalized to the content of β-actin. h The expression of VEGFR-1 in PC-3M-luc2 tumors normalized to the content of β-actin. i Plasma concentration of TGF-β1 in mice bearing PC-3M-luc2 tumors. All data are presented as mean ± SD values